Efficacy News and Research

RSS

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Two studies presented today at the American Academy of Neurology (AAN) 56th Annual Meeting show that pregabalin, when used as an add-on treatment for epilepsy, does not affect male reproductive function or interfere with the effectiveness of oral contraceptives.

29 Apr 2004

Body repositioning is highly effective in resolving dizziness

Dizziness is one of the most common medical complaints affecting older adults, with 10-20 percent of such complaints resulting from Benign Paroxysmal Positional Vertigo (BPPV). Many research studies have stated that without medical treatment, some 30 percent of BPPV patients will recover on their own. Now, a new evidence-based review has found that a single ten minute in-office treatment, based on a series of head and body turns, is highly effective in resolving this disorder, with an overall effectiveness of 70-80 percent.

29 Apr 2004

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Results from a large-scale, randomized, double-blind study show MIRAPEX(R) (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS).

28 Apr 2004

FDA requires pancreatic extract manufacturers to get approval to remain on the market

The Food and Drug Administration (FDA) today formally notified manufacturers of pancreatic insufficiency products that these drugs must get approval by FDA within the next four years in order to remain on the market.

28 Apr 2004

Estimates vary, but as much as 20% of new prescriptions never get filled and 85% of refills never leave the pharmacy

Furthermore, a study conducted by the University of Arizona's School of Pharmacy finds that 40% of patients who receive outpatient drug therapy will experience a treatment failure or new medical problem as a result of improper use.

28 Apr 2004

$Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year$

Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year

Results of a new analysis found that, without treatment, one out of 13 postmenopausal osteoporotic women who were initially fracture-free were likely to experience a spinal fracture within one year.

28 Apr 2004

Inspire announces positive results in cystic fibrosis study

Inspire Pharmaceuticals, Inc. today announced top-line results in a Phase II study of INS37217 Respiratory in patients with mild cystic fibrosis (CF) lung disease.

27 Apr 2004

Parkinson’s disease drug Pergolide effective in treating restless legs syndrome

Pergolide, a drug commonly used to treat Parkinson’s disease symptoms, has recently been shown to be effective in treating restless legs syndrome. Researchers from seven countries collaborated on the study, published in the April 27 issue of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2004

Overview of West Nile virus before season starts

West Nile virus is a newly emergent virus of the family Flaviviridae, found in both tropical and temperate regions. It mainly infects birds, but is also the cause of a number of conditions in humans, horses, and some other mammals. It is transmitted by bites of infected mosquitoes.

24 Apr 2004

The April 2004 issue of Otolaryngology focuses on head and neck surgery

The efficacy of a new cancer-fighting virus is tested in the study, “Treatment of Solid Sarcomas in Immunocompetent Mice with Novel Oncolytic Herpes Simplex Viruses.” A team of multi-disciplinary Japanese researchers found that a weakened version of herpes simplex virus (HSV) effectively eradicated neck and flank tumors in mice.

23 Apr 2004

GSK and WHO collaborate to fight malaria

GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.

23 Apr 2004

SSRI antidepressants may be unsuitable for children

A UK study in this week's issue of THE LANCET suggests that reliance on published studies alone to guide the treatment of childhood depression could be inappropriate. A systematic review including published and unpublished data shows that only one drug, fluoxetine (Prozac), was not associated with negative outcomes for children with depression.

22 Apr 2004

Clinical trial of curcumin in people with cystic fibrosis

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that it is funding a clinical trial of curcumin in people with cystic fibrosis (CF).

22 Apr 2004

WHO renews call for effective malaria treatment

More than 600 million people, most of them children living in sub-Saharan Africa, face the daily threat of death from malaria because new, effective treatments are not available where they live. Existing, cheaper medicines, which have been used for many years, are no longer effective in most places because the malaria parasite has developed resistance to them.

22 Apr 2004

FDA approval for drug to treat attention deficit hyperactivity disorder

McNeil Consumer & Specialty Pharmaceuticals has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the use of CONCERTA® (methylphenidate HCl) CII Extended-release Tablets in adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) and to expand labeling to include a 72 mg dosing regimen.

22 Apr 2004

Fish oil reduces heart attack and blood vessel disease

Fish oil can help reduce deaths from heart disease, according to new evidence reports announced today by the Agency for Healthcare Research and Quality.

22 Apr 2004

FDA approves Advair Diskus® for children with asthma

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.

22 Apr 2004

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

Cardiac Science receives warning from FDA

Cardiac Science, Inc., a leading manufacturer of life-saving automated public-access defibrillators (AED) and provider of comprehensive AED/CPR training services, said today that it received a Warning Letter following a routine inspection of its manufacturing facility in Minneapolis conducted by the U.S. Food and Drug Administration

20 Apr 2004